Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial - PubMed (original) (raw)
Clinical Trial
Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial
G Sundkvist et al. J Diabetes Complications. 1992 Apr-Jun.
Abstract
The potential of the aldose reductase inhibitor ponalrestat (600 mg daily) to ameliorate diabetic neuropathy was evaluated in 259 diabetes mellitus patients with peripheral neuropathy (defined by abnormal vibration perception threshold and abnormal peroneal motor conduction velocity) in a double-blind placebo-controlled clinical trial running for 18 months. Overall, no beneficial effect of ponalrestat on vibration perception thresholds, nerve conduction velocities, and nerve action potential amplitudes was detected. Because vibration perception thresholds and conduction velocities in median, peroneal, and sural nerves did not deteriorate in the placebo group, the potential of ponalrestat to prevent the expected deterioration in peripheral nerve function that occurs with an increased duration of diabetes was not tested. Patients with an abnormal heart rate reaction to standing (abnormal 30:15 ratio; n = 84) on ponalrestat did not deteriorate in this autonomic nerve function test as shown in those on placebo. In conclusion, ponalrestat did not improve peripheral nerve function in diabetes mellitus patients with signs of peripheral neuropathy, although it did ameliorate a deterioration in autonomic nerve function in diabetic patients with signs of autonomic neuropathy.
Similar articles
- Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
Valensi P, Attali JR, Gagant S. Valensi P, et al. Diabet Med. 1993 Dec;10(10):933-9. doi: 10.1111/j.1464-5491.1993.tb00009.x. Diabet Med. 1993. PMID: 8306589 Clinical Trial. - A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M. Krentz AJ, et al. Diabet Med. 1992 Jun;9(5):463-8. doi: 10.1111/j.1464-5491.1992.tb01818.x. Diabet Med. 1992. PMID: 1611835 Clinical Trial. - Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Boland OM, Blackwell CC, Clarke BF, Ewing DJ. Boland OM, et al. Diabetes. 1993 Feb;42(2):336-40. doi: 10.2337/diab.42.2.336. Diabetes. 1993. PMID: 8425670 Clinical Trial. - Recent clinical experience with aldose reductase inhibitors.
Krans HM. Krans HM. Diabet Med. 1993;10 Suppl 2:44S-48S. doi: 10.1111/j.1464-5491.1993.tb00198.x. Diabet Med. 1993. PMID: 8334842 Review. No abstract available. - WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Airey M, Bennett C, Nicolucci A, Williams R. Airey M, et al. Cochrane Database Syst Rev. 1996 Apr 22;(1):CD002182. doi: 10.1002/14651858.CD002182. Cochrane Database Syst Rev. 1996. PMID: 17636697 Review.
Cited by
- Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?
Al-Bazz DY, Nelson AJ, Burgess J, Petropoulos IN, Nizza J, Marshall A, Brown E, Cuthbertson DJ, Marshall AG, Malik RA, Alam U. Al-Bazz DY, et al. Diagnostics (Basel). 2022 Mar 17;12(3):731. doi: 10.3390/diagnostics12030731. Diagnostics (Basel). 2022. PMID: 35328284 Free PMC article. Review. - Physiological and Pathological Roles of Aldose Reductase.
Singh M, Kapoor A, Bhatnagar A. Singh M, et al. Metabolites. 2021 Sep 27;11(10):655. doi: 10.3390/metabo11100655. Metabolites. 2021. PMID: 34677370 Free PMC article. Review. - Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease.
Chang KC, Petrash JM. Chang KC, et al. Adv Exp Med Biol. 2018;1032:173-202. doi: 10.1007/978-3-319-98788-0_13. Adv Exp Med Biol. 2018. PMID: 30362099 Free PMC article. Review. - Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis.
Hu X, Li S, Yang G, Liu H, Boden G, Li L. Hu X, et al. PLoS One. 2014 Feb 12;9(2):e87096. doi: 10.1371/journal.pone.0087096. eCollection 2014. PLoS One. 2014. PMID: 24533052 Free PMC article. Review. - Diabetic neuropathy part 1: overview and symmetric phenotypes.
Pasnoor M, Dimachkie MM, Kluding P, Barohn RJ. Pasnoor M, et al. Neurol Clin. 2013 May;31(2):425-45. doi: 10.1016/j.ncl.2013.02.004. Epub 2013 Mar 15. Neurol Clin. 2013. PMID: 23642717 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical